We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PFIZER: ALPHARMA-TEVA DEAL VIOLATES 180-DAY RULE
PFIZER: ALPHARMA-TEVA DEAL VIOLATES 180-DAY RULE
May 21, 2004
The recent agreement between generic firms Teva Pharmaceutical and Alpharma to co-market a version of Pifzer’s epilepsy drug Neurontin (gabapentin) during Alpharma’s 180-day marketing exclusivity period violates federal drug laws governing generic exclusivity, Pfizer said in a citizen petition that argues exclusivity is not a right that can be transfered.